We evaluated urine NGAL, KIM-1, TIMP-2, and IGFBP-7, collected during cisplatin infusions early in cancer therapy (early visit [EV]) and later in cancer therapy (late visit [LV]), for predicting signs of CKD and HTN at 3 months after cisplatin therapy completion. This evidence concerns the gene LCN2 and hypertensive disorder.